The immunology landscape is one of the fastest-evolving domains in life sciences, shaped by breakthroughs in autoimmune therapies, biologics, cell and gene technologies, and precision immunomodulation. With rising scientific complexity, shifting regulatory expectations, and intensifying competition, healthcare executives and investors increasingly rely on specialized market research firms to de-risk decisions and accelerate strategic planning.
This list highlights the top 10 healthcare market research firms in immunology, evaluated for their data depth, therapeutic expertise, analytic capabilities, forecasting sophistication, client service quality, and strategic relevance to biopharma and medtech stakeholders.
IQVIA remains the most comprehensive source of global healthcare intelligence for immunology. Its unparalleled datasets—spanning claims, EMR, prescription, specialty pharmacy, and real-world evidence—make it indispensable for teams developing, launching, and commercializing immunology assets.
IQVIA’s advanced AI-driven analytics enable detailed market sizing, patient segmentation, treatment pattern mapping, and forecasting across autoimmune diseases such as rheumatoid arthritis, IBD, psoriasis, multiple sclerosis, and rare immunological conditions. Its consulting division supports pricing, payer strategy, and real-world outcomes modelling essential for high-stakes immunology launches.
The company’s continuous investment in real-world data, omnichannel analytics, and connected intelligence platforms positions it as the top resource for executives needing robust, end-to-end immunology market insights.
Clarivate, integrating Decision Resources Group (DRG) and Cortellis capabilities, provides an exceptional blend of scientific, clinical, commercial, and regulatory intelligence for immunology markets.
Its syndicated immunology reports, epidemiology models, mechanism-of-action databases, and pipeline analytics give teams a 360-degree view of autoimmune and inflammatory disease dynamics. Clarivate’s analyst network delivers expert commentary on emerging pathways, immunomodulators, biosimilars, and late-stage assets—critical for competitive benchmarking and portfolio prioritization.
The firm’s ability to connect early scientific signals with commercial feasibility makes it particularly valuable for strategy teams assessing new opportunities in immunology’s rapidly expanding therapeutic classes.
Evaluate Pharma provides best-in-class forecasting tools, market models, and consensus estimates widely used by investor relations teams, corporate strategists, and BD/M&A groups in immunology.
Its immunology datasets cover drug revenue projections, peak sales estimates, pipeline PTSR (probability of success) modelling, and analyst consensus narratives across leading autoimmune and inflammatory categories. Combined with Biomedtracker’s competitive intelligence, Evaluate offers a forward-looking perspective into immunology pipelines, risk-adjusted valuations, and potential dealmaking trends.
For organizations evaluating licensing, acquisition targets, or revenue expectations for new immunology therapies, Evaluate delivers clarity and strategic direction supported by transparent methodologies.
Ranked fourth on this list, DelveInsight is a highly respected niche market research and consulting firm with deep therapeutic expertise across immunology.
Its strengths include:
Comprehensive disease-specific market reports (e.g., RA, UC, Crohn’s, SLE, atopic dermatitis, ankylosing spondylitis)
Detailed epidemiology models and patient population analytics
Competitive landscapes tracking clinical-stage and marketed immunology assets
HTA, pricing, and access analyses
Tailored consulting for competitive intelligence, due diligence, and portfolio strategy
DelveInsight’s specialized analyst teams deliver high-resolution insights into disease mechanisms, emerging modalities, clinical development trends, and competitive threats. For mid-sized biotechs, global pharma, and investors seeking actionable, therapy-level intelligence, DelveInsight provides depth and customizability that large vendors often cannot match.
Informa Pharma Intelligence, including Citeline (previously Pharma Intelligence), is a top-tier provider of clinical trial, investigator, and pipeline analytics for immunology.
Its real-time clinical trial registries, protocol benchmarking tools, and indication-specific databases offer executives a granular understanding of trial feasibility, study design norms, biomarker usage, and sponsor activity across autoimmune and inflammatory disorders.
Informa’s industry events, scientific coverage, and editorial analysis also keep teams informed on immunology advancements in biologics, biosimilars, and next-generation immunotherapies. This makes it an essential resource for R&D planning, trial optimization, and competitive tracking.
Frost & Sullivan’s healthcare and life sciences practice provides strategic market sizing, growth opportunity analysis, and competitive frameworks highly relevant to companies in immunology, particularly those in diagnostics, biomarkers, and immunotherapy platforms.
Their reports highlight evolving white-space opportunities, technology adoption curves, payer shifts, and unmet needs across immunology’s sub-segments. Frost’s consulting arm also helps companies develop commercialization roadmaps, market entry strategies, and product positioning for immunology solutions.
Executives turn to Frost & Sullivan when they need growth-oriented insights rather than purely scientific or clinical intelligence.
McKinsey’s Life Sciences practice provides executive-level strategy consulting informed by proprietary benchmarks, real-world analytics, and deep expertise in immunology innovation.
While not a traditional data vendor, McKinsey’s strength lies in translating immunology market intelligence into enterprise-level transformation initiatives—such as R&D model redesign, immunology franchise optimization, AI/ML adoption, launch excellence, and payer strategy refinement.
Organizations developing high-impact autoimmune portfolios often rely on McKinsey for decision frameworks and capability building that extend beyond typical market research deliverables.
8. GlobalData Healthcare – Broad Immunology Market Monitoring and Forecasting
GlobalData provides a wide suite of syndicated reports, competitive trackers, and market models spanning major immunology indications. Their coverage includes epidemiology, treatment trends, drug uptake, pricing landscapes, and late-stage competitive analysis.
GlobalData’s forecasts offer directional guidance for commercial teams assessing disease landscape evolution, therapy positioning, and market-entry potential. They also produce frequent intelligence updates that help organizations stay ahead of regulatory, scientific, and market changes across immunology.
Kantar Health, which now operates under Clarivate, has historically been recognized for its strong patient-reported outcomes, behavioral insights, and real-world research capabilities across immunology.
Its focus on patient journeys, adherence patterns, treatment preferences, and physician decision drivers makes it particularly valuable for brand teams and market access groups. Even as part of Clarivate, its methodological legacy continues to support nuanced immunology insight generation grounded in real human behavior rather than only quantitative datasets.
Syneos Health combines data, consulting, and commercialization execution, making it a strong partner for immunology companies approaching launch or scaling commercialization activities.
Its insights help teams understand market barriers, KOL perceptions, payer challenges, and customer engagement expectations within complex immunology categories. Its integrated model—research plus commercialization support—creates value for companies needing both intelligence and hands-on operational execution.
What Makes a Strong Immunology Market Research Partner?
Immunology is uniquely complex. Choosing the right market research firm requires careful assessment of capabilities across several dimensions:
Therapeutic expertise across autoimmune, inflammatory, and immune-mediated rare diseases
Depth and transparency of epidemiology modelling
Strength of clinical trial and pipeline analytics
Real-world evidence quality and availability
Forecasting sophistication for biologics, biosimilars, and novel modalities
Pricing and market-access intelligence for rapidly shifting payer landscapes
Competitive intelligence capabilities spanning MoA, assets, and clinical differentiation
Flexibility for custom research to support nuanced strategic questions
Ability to inform cross-functional teams, from R&D to commercialization and finance
Organizations typically benefit from combining one large data provider with one specialty immunology research firm.
Final Thoughts: Choosing the Right Immunology Market Research Firm in 2025
As the immunology market accelerates—driven by biologics innovation, biosimilar expansion, precision immunotherapies, and real-world evidence requirements—robust market intelligence becomes mission-critical for pharma, medtech, and investors.
The firms listed above offer varying strengths:
IQVIA and Clarivate for enterprise data and analytics scale
Evaluate for forecasting and valuation
DelveInsight for deep therapy-specific insights and customized analysis
Informa for pipeline and trial intelligence
Frost & Sullivan for strategic growth opportunities
McKinsey for high-level transformation and portfolio decisions
Selecting the right mix enables organizations to make faster, more confident decisions across R&D, BD/M&A, commercialization, and investment strategy. In an era where immunology competition intensifies each year, the advantage increasingly belongs to teams that leverage the strongest insights—first, and most effectively.